-+ 0.00%
-+ 0.00%
-+ 0.00%

Immunocore reports 70% two-year survival in metastatic uveal melanoma combination trial

PUBT·11/06/2026 17:01:52
Listen to the news
Immunocore reports 70% two-year survival in metastatic uveal melanoma combination trial
  • Immunocore presented Phase 1/2 results for brenetafusp combined with Kimmtrak in metastatic uveal melanoma on November 6, 2026.
  • The combination showed sustained tumor responses and encouraging survival outcomes in previously untreated patients, with manageable side effects and no new safety signals.
  • An oral presentation of the results is scheduled for November 7, 2026, at the Society for Immunotherapy of Cancer meeting.
  • A randomized Phase 2/3 trial, DUET-UVEAL, is planned to further evaluate the combination in adults with unresectable or metastatic uveal melanoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.